Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model.

Weijun Wang, Adel Kardosh, Yuzhuang S. Su, Axel H. Schonthal, Thomas C. Chen

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

OBJECT: The incidence of primary central nervous system lymphomas (PCNSLs) has increased over the past several decades. Unfortunately, even with the most effective therapeutic regimen (that is, methotrexate with wholebrain radiation therapy), PCNSL recurs within a few years in more than half of the treated patients and is eventually fatal. Because PCNSL usually occurs in older patients and in those with acquired immunodeficiency syndrome, combination treatments in which both chemo- and radiation therapy are used is often poorly tolerated and results in a significant reduction in the quality of life. Recently, it has been demonstrated that the selective cyclooxygenase- 2 inhibitor celecoxib (Celebrex), can block the growth of lymphoma cells in vitro. METHODS: To create an experimental animal model in vivo for the PCNSL study, the authors intracranially injected a human B-cell lymphoma cell line into nude mice. Their data demonstrate that this experimental model is an excellent one for human PCNSL with brain and leptomeningeal involvement. They also evaluated the feasibility of using celecoxib as a therapeutic agent in the treatment of PCNSL. Nude mice with intracranial lymphomas were treated with celecoxib contained in the animal chow. The treated animals demonstrated significantly prolonged survival times compared with the untreated animals. CONCLUSIONS: Based on the authors' data, celecoxib may be a promising therapeutic agent for the treatment of PCNSL.

Original languageEnglish (US)
JournalNeurosurgical focus
Volume21
Issue number5
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

Celecoxib
Lymphoma
Central Nervous System
Therapeutics
Nude Mice
Radiotherapy
Cyclooxygenase 2 Inhibitors
B-Cell Lymphoma

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Wang, W., Kardosh, A., Su, Y. S., Schonthal, A. H., & Chen, T. C. (2006). Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model. Neurosurgical focus, 21(5).

Efficacy of celecoxib in the treatment of CNS lymphomas : an in vivo model. / Wang, Weijun; Kardosh, Adel; Su, Yuzhuang S.; Schonthal, Axel H.; Chen, Thomas C.

In: Neurosurgical focus, Vol. 21, No. 5, 01.01.2006.

Research output: Contribution to journalArticle

Wang, Weijun ; Kardosh, Adel ; Su, Yuzhuang S. ; Schonthal, Axel H. ; Chen, Thomas C. / Efficacy of celecoxib in the treatment of CNS lymphomas : an in vivo model. In: Neurosurgical focus. 2006 ; Vol. 21, No. 5.
@article{8004e9968c8a4a3297ea118a4cbcd169,
title = "Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model.",
abstract = "OBJECT: The incidence of primary central nervous system lymphomas (PCNSLs) has increased over the past several decades. Unfortunately, even with the most effective therapeutic regimen (that is, methotrexate with wholebrain radiation therapy), PCNSL recurs within a few years in more than half of the treated patients and is eventually fatal. Because PCNSL usually occurs in older patients and in those with acquired immunodeficiency syndrome, combination treatments in which both chemo- and radiation therapy are used is often poorly tolerated and results in a significant reduction in the quality of life. Recently, it has been demonstrated that the selective cyclooxygenase- 2 inhibitor celecoxib (Celebrex), can block the growth of lymphoma cells in vitro. METHODS: To create an experimental animal model in vivo for the PCNSL study, the authors intracranially injected a human B-cell lymphoma cell line into nude mice. Their data demonstrate that this experimental model is an excellent one for human PCNSL with brain and leptomeningeal involvement. They also evaluated the feasibility of using celecoxib as a therapeutic agent in the treatment of PCNSL. Nude mice with intracranial lymphomas were treated with celecoxib contained in the animal chow. The treated animals demonstrated significantly prolonged survival times compared with the untreated animals. CONCLUSIONS: Based on the authors' data, celecoxib may be a promising therapeutic agent for the treatment of PCNSL.",
author = "Weijun Wang and Adel Kardosh and Su, {Yuzhuang S.} and Schonthal, {Axel H.} and Chen, {Thomas C.}",
year = "2006",
month = "1",
day = "1",
language = "English (US)",
volume = "21",
journal = "Neurosurgical Focus",
issn = "1092-0684",
publisher = "American Association of Neurological Surgeons",
number = "5",

}

TY - JOUR

T1 - Efficacy of celecoxib in the treatment of CNS lymphomas

T2 - an in vivo model.

AU - Wang, Weijun

AU - Kardosh, Adel

AU - Su, Yuzhuang S.

AU - Schonthal, Axel H.

AU - Chen, Thomas C.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - OBJECT: The incidence of primary central nervous system lymphomas (PCNSLs) has increased over the past several decades. Unfortunately, even with the most effective therapeutic regimen (that is, methotrexate with wholebrain radiation therapy), PCNSL recurs within a few years in more than half of the treated patients and is eventually fatal. Because PCNSL usually occurs in older patients and in those with acquired immunodeficiency syndrome, combination treatments in which both chemo- and radiation therapy are used is often poorly tolerated and results in a significant reduction in the quality of life. Recently, it has been demonstrated that the selective cyclooxygenase- 2 inhibitor celecoxib (Celebrex), can block the growth of lymphoma cells in vitro. METHODS: To create an experimental animal model in vivo for the PCNSL study, the authors intracranially injected a human B-cell lymphoma cell line into nude mice. Their data demonstrate that this experimental model is an excellent one for human PCNSL with brain and leptomeningeal involvement. They also evaluated the feasibility of using celecoxib as a therapeutic agent in the treatment of PCNSL. Nude mice with intracranial lymphomas were treated with celecoxib contained in the animal chow. The treated animals demonstrated significantly prolonged survival times compared with the untreated animals. CONCLUSIONS: Based on the authors' data, celecoxib may be a promising therapeutic agent for the treatment of PCNSL.

AB - OBJECT: The incidence of primary central nervous system lymphomas (PCNSLs) has increased over the past several decades. Unfortunately, even with the most effective therapeutic regimen (that is, methotrexate with wholebrain radiation therapy), PCNSL recurs within a few years in more than half of the treated patients and is eventually fatal. Because PCNSL usually occurs in older patients and in those with acquired immunodeficiency syndrome, combination treatments in which both chemo- and radiation therapy are used is often poorly tolerated and results in a significant reduction in the quality of life. Recently, it has been demonstrated that the selective cyclooxygenase- 2 inhibitor celecoxib (Celebrex), can block the growth of lymphoma cells in vitro. METHODS: To create an experimental animal model in vivo for the PCNSL study, the authors intracranially injected a human B-cell lymphoma cell line into nude mice. Their data demonstrate that this experimental model is an excellent one for human PCNSL with brain and leptomeningeal involvement. They also evaluated the feasibility of using celecoxib as a therapeutic agent in the treatment of PCNSL. Nude mice with intracranial lymphomas were treated with celecoxib contained in the animal chow. The treated animals demonstrated significantly prolonged survival times compared with the untreated animals. CONCLUSIONS: Based on the authors' data, celecoxib may be a promising therapeutic agent for the treatment of PCNSL.

UR - http://www.scopus.com/inward/record.url?scp=39049181328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049181328&partnerID=8YFLogxK

M3 - Article

C2 - 17134116

AN - SCOPUS:39049181328

VL - 21

JO - Neurosurgical Focus

JF - Neurosurgical Focus

SN - 1092-0684

IS - 5

ER -